Phenotype Microarrays™

Total Page:16

File Type:pdf, Size:1020Kb

Phenotype Microarrays™ Phenotype MicroArrays™ PM11C MicroPlate™ A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 Amikacin Amikacin Amikacin Amikacin Chlortetracycline Chlortetracycline Chlortetracycline Chlortetracycline Lincomycin Lincomycin Lincomycin Lincomycin 1 2 3 4 1 2 3 4 1 2 3 4 B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 Amoxicillin Amoxicillin Amoxicillin Amoxicillin Cloxacillin Cloxacillin Cloxacillin Cloxacillin Lomefloxacin Lomefloxacin Lomefloxacin Lomefloxacin 1 2 3 4 1 2 3 4 1 2 3 4 C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 Bleomycin Bleomycin Bleomycin Bleomycin Colistin Colistin Colistin Colistin Minocycline Minocycline Minocycline Minocycline 1 2 3 4 1 2 3 4 1 2 3 4 D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 Capreomycin Capreomycin Capreomycin Capreomycin Demeclocycline Demeclocycline Demeclocycline Demeclocycline Nafcillin Nafcillin Nafcillin Nafcillin 1 2 3 4 1 2 3 4 1 2 3 4 E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 Cefazolin Cefazolin Cefazolin Cefazolin Enoxacin Enoxacin Enoxacin Enoxacin Nalidixic acid Nalidixic acid Nalidixic acid Nalidixic acid 1 2 3 4 1 2 3 4 1 2 3 4 F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 Chloramphenicol Chloramphenicol Chloramphenicol Chloramphenicol Erythromycin Erythromycin Erythromycin Erythromycin Neomycin Neomycin Neomycin Neomycin 1 2 3 4 1 2 3 4 1 2 3 4 G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G12 Ceftriaxone Ceftriaxone Ceftriaxone Ceftriaxone Gentamicin Gentamicin Gentamicin Gentamicin Potassium Potassium Potassium Potassium tellurite tellurite tellurite tellurite 1 2 3 4 1 2 3 4 1 2 3 4 H1 H2 H3 H4 H5 H6 H7 H8 H9 H10 H11 H12 Cephalothin Cephalothin Cephalothin Cephalothin Kanamycin Kanamycin Kanamycin Kanamycin Ofloxacin Ofloxacin Ofloxacin Ofloxacin 1 2 3 4 1 2 3 4 1 2 3 4 PM12B MicroPlate™ A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 Penicillin G Penicillin G Penicillin G Penicillin G Tetracycline Tetracycline Tetracycline Tetracycline Carbenicillin Carbenicillin Carbenicillin Carbenicillin 1 2 3 4 1 2 3 4 1 2 3 4 B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 Oxacillin Oxacillin Oxacillin Oxacillin Penimepicycline Penimepicycline Penimepicycline Penimepicycline Polymyxin B Polymyxin B Polymyxin B Polymyxin B 1 2 3 4 1 2 3 4 1 2 3 4 C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 Paromomycin Paromomycin Paromomycin Paromomycin Vancomycin Vancomycin Vancomycin Vancomycin D,L-Serine D,L-Serine D,L-Serine D,L-Serine hydroxamate hydroxamate hydroxamate hydroxamate 1 2 3 4 1 2 3 4 1 2 3 4 D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 Sisomicin Sisomicin Sisomicin Sisomicin Sulfamethazine Sulfamethazine Sulfamethazine Sulfamethazine Novobiocin Novobiocin Novobiocin Novobiocin 1 2 3 4 1 2 3 4 1 2 3 4 E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 2,4-Diamino-6,7- 2,4-Diamino-6,7- 2,4-Diamino-6,7- 2,4-Diamino-6,7- Sulfadiazine Sulfadiazine Sulfadiazine Sulfadiazine Benzethonium Benzethonium Benzethonium Benzethonium diisopropyl- diisopropyl- diisopropyl- diisopropyl- chloride chloride chloride chloride pteridine pteridine pteridine pteridine 1 2 3 4 1 2 3 4 1 2 3 4 F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 Tobramycin Tobramycin Tobramycin Tobramycin Sulfathiazole Sulfathiazole Sulfathiazole Sulfathiazole 5-Fluoroorotic 5-Fluoroorotic 5-Fluoroorotic 5-Fluoroorotic acid acid acid acid 1 2 3 4 1 2 3 4 1 2 3 4 G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G12 Spectinomycin Spectinomycin Spectinomycin Spectinomycin Sulfa- Sulfa- Sulfa- Sulfa- L-Aspartic-β- L-Aspartic-β- L-Aspartic-β- L-Aspartic-β- methoxazole methoxazole methoxazole methoxazole hydroxamate hydroxamate hydroxamate hydroxamate 1 2 3 4 1 2 3 4 1 2 3 4 H1 H2 H3 H4 H5 H6 H7 H8 H9 H10 H11 H12 Spiramycin Spiramycin Spiramycin Spiramycin Rifampicin Rifampicin Rifampicin Rifampicin Dodecyltrimethyl Dodecyltrimethyl Dodecyltrimethyl Dodecyltrimethyl ammonium ammonium ammonium ammonium bromide bromide bromide bromide 1 2 3 4 1 2 3 4 1 2 3 4 Phenotype MicroArrays™ PM13B MicroPlate™ A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 Ampicillin Ampicillin Ampicillin Ampicillin Dequalinium Dequalinium Dequalinium Dequalinium Nickel chloride Nickel chloride Nickel chloride Nickel chloride chloride chloride chloride chloride 1 2 3 4 1 2 3 4 1 2 3 4 B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 Azlocillin Azlocillin Azlocillin Azlocillin 2, 2'-Dipyridyl 2, 2'-Dipyridyl 2, 2'-Dipyridyl 2, 2'-Dipyridyl Oxolinic acid Oxolinic acid Oxolinic acid Oxolinic acid 1 2 3 4 1 2 3 4 1 2 3 4 C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 6-Mercapto- 6-Mercapto- 6-Mercapto- 6-Mercapto- Doxycycline Doxycycline Doxycycline Doxycycline Potassium Potassium Potassium Potassium purine purine purine purine chromate chromate chromate chromate 1 2 3 4 1 2 3 4 1 2 3 4 D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 Cefuroxime Cefuroxime Cefuroxime Cefuroxime 5-Fluorouracil 5-Fluorouracil 5-Fluorouracil 5-Fluorouracil Rolitetracycline Rolitetracycline Rolitetracycline Rolitetracycline 1 2 3 4 1 2 3 4 1 2 3 4 E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 Cytosine-1-beta- Cytosine-1-beta- Cytosine-1-beta- Cytosine-1-beta- Geneticin (G418) Geneticin (G418) Geneticin (G418) Geneticin (G418) Ruthenium red Ruthenium red Ruthenium red Ruthenium red D-arabino- D-arabino- D-arabino- D-arabino- furanoside furanoside furanoside furanoside 1 2 3 4 1 2 3 4 1 2 3 4 F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 Cesium chloride Cesium chloride Cesium chloride Cesium chloride Glycine Glycine Glycine Glycine Thallium (I) Thallium (I) Thallium (I) Thallium (I) acetate acetate acetate acetate 1 2 3 4 1 2 3 4 1 2 3 4 G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G12 Cobalt chloride Cobalt chloride Cobalt chloride Cobalt chloride Manganese Manganese Manganese Manganese Trifluoperazine Trifluoperazine Trifluoperazine Trifluoperazine chloride chloride chloride chloride 1 2 3 4 1 2 3 4 1 2 3 4 H1 H2 H3 H4 H5 H6 H7 H8 H9 H10 H11 H12 Cupric chloride Cupric chloride Cupric chloride Cupric chloride Moxalactam Moxalactam Moxalactam Moxalactam Tylosin Tylosin Tylosin Tylosin 1 2 3 4 1 2 3 4 1 2 3 4 PM14A MicroPlate™ A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 Acriflavine Acriflavine Acriflavine Acriflavine Furaltadone Furaltadone Furaltadone Furaltadone Sanguinarine Sanguinarine Sanguinarine Sanguinarine 1 2 3 4 1 2 3 4 1 2 3 4 B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 9-Aminoacridine 9-Aminoacridine 9-Aminoacridine 9-Aminoacridine Fusaric acid Fusaric acid Fusaric acid Fusaric acid Sodium arsenate Sodium arsenate Sodium arsenate Sodium arsenate 1 2 3 4 1 2 3 4 1 2 3 4 C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 Boric Acid Boric Acid Boric Acid Boric Acid 1-Hydroxy- 1-Hydroxy- 1-Hydroxy- 1-Hydroxy- Sodium cyanate Sodium cyanate Sodium cyanate Sodium cyanate pyridine -2- pyridine -2- pyridine -2- pyridine -2- thione thione thione thione 1 2 3 4 1 2 3 4 1 2 3 4 D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 Cadmium Cadmium Cadmium Cadmium Iodoacetate Iodoacetate Iodoacetate Iodoacetate Sodium Sodium Sodium Sodium chloride chloride chloride chloride dichromate dichromate dichromate dichromate 1 2 3 4 1 2 3 4 1 2 3 4 E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 Cefoxitin Cefoxitin Cefoxitin Cefoxitin Nitrofurantoin Nitrofurantoin Nitrofurantoin Nitrofurantoin Sodium Sodium Sodium Sodium metaborate metaborate metaborate metaborate 1 2 3 4 1 2 3 4 1 2 3 4 F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 Chloramphenicol Chloramphenicol Chloramphenicol Chloramphenicol Piperacillin Piperacillin Piperacillin Piperacillin Sodium Sodium Sodium Sodium metavanadate metavanadate metavanadate metavanadate 1 2 3 4 1 2 3 4 1 2 3 4 G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G12 Chelerythrine Chelerythrine Chelerythrine Chelerythrine Carbenicillin Carbenicillin Carbenicillin Carbenicillin Sodium nitrite Sodium nitrite Sodium nitrite Sodium nitrite 1 2 3 4 1 2 3 4 1 2 3 4 H1 H2 H3 H4 H5 H6 H7 H8 H9 H10 H11 H12 EGTA EGTA EGTA EGTA Promethazine Promethazine Promethazine Promethazine Sodium Sodium Sodium Sodium orthovanadate orthovanadate orthovanadate orthovanadate 1 2 3 4 1 2 3 4 1 2 3 4 Phenotype MicroArrays™ PM15B MicroPlate™ A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 Procaine Procaine Procaine Procaine Guanidine Guanidine Guanidine Guanidine Cefmetazole Cefmetazole Cefmetazole Cefmetazole hydrochloride hydrochloride hydrochloride hydrochloride 1 2 3 4 1 2 3 4 1 2 3 4 B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 D-Cycloserine D-Cycloserine D-Cycloserine D-Cycloserine EDTA EDTA EDTA EDTA 5,7-Dichloro- 8- 5,7-Dichloro- 8- 5,7-Dichloro- 8- 5,7-Dichloro- 8- hydroxy- hydroxy- hydroxy- hydroxy- quinaldine quinaldine quinaldine quinaldine 1 2 3 4 1 2 3 4 1 2 3 4 C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 5,7-Dichloro-8- 5,7-Dichloro-8- 5,7-Dichloro-8- 5,7-Dichloro-8- Fusidic acid Fusidic acid Fusidic acid Fusidic acid 1,10- 1,10- 1,10- 1,10- hydroxyquinoline hydroxyquinoline hydroxyquinoline hydroxyquinoline Phenanthroline Phenanthroline Phenanthroline Phenanthroline 1 2 3 4 1 2 3 4 1 2 3 4 D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 Phleomycin Phleomycin Phleomycin Phleomycin Domiphen Domiphen Domiphen Domiphen Nordihydroguaia Nordihydroguaia Nordihydroguaia Nordihydroguaia bromide bromide bromide bromide retic acid retic acid retic acid retic acid 1 2 3 4 1 2 3 4 1 2 3 4 E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 Alexidine Alexidine Alexidine Alexidine 5-Nitro-2- 5-Nitro-2- 5-Nitro-2- 5-Nitro-2- Methyl viologen Methyl viologen Methyl viologen Methyl viologen furaldehyde furaldehyde furaldehyde furaldehyde semicarbazone semicarbazone semicarbazone semicarbazone 1 2 3 4 1 2 3 4 1 2 3 4 F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 3, 4-Dimethoxy- 3, 4-Dimethoxy- 3, 4-Dimethoxy- 3, 4-Dimethoxy- Oleandomycin Oleandomycin Oleandomycin Oleandomycin Puromycin Puromycin Puromycin Puromycin benzyl alcohol benzyl alcohol benzyl alcohol benzyl alcohol
Recommended publications
  • Technical Information
    Technical Information Antibiotic Assay Medium No.1 (Seed Agar) Product Code : DM1003 Application: - Antibiotic Assay Medium No.1 (Seed Agar) is used in the microbiological assay of beta-lactam and other antibiotics. Composition** Ingredients Gms / Litre Peptic digest of animal tissue (Peptone) 6.000 or detecting faecal coliforms drinking in water waste water, seawater and foods samples by MPN Method. Casein enzymic hydrolysate 4.000 Yeast extract 3.000 Beef extract 1.500 Dextrose 1.000 Agar 15.000 Final pH (at 25°C) 6.6±0.2 **Formula adjusted, standardized to suit performance parameters Principle & Interpretation The potency of an antibiotic can be determined by chemical, physical and biological methods. An assay is performed to determine the ability of an antibiotic to kill or inhibit the growth of living microorganisms. Biological tests offer the most convenient m eans of performing an assay (1), since a reduction in the antimicrobial activity of a specific antibiotic reveals changes that is not usually displayed by chemical methods (2). Antibacterial susceptibility testing may be performed by either dilution (turbidimetric) or diffusion methods. The choice o f methodology is based on many factors, including ease of performance, flexibility and use of automated or semi-automated devices for both identification and susceptibility testing (3). Grove and Randall have elucidated antibiotic assays and media in their comprehensive treatise on antibiotic assays (4). Antibiotic Assay Medium No.1 is used in the microbiological assay of ß-lactam and other antibiotics. These media are prepared according to the specifications detailed in various pharmacopoeias (2-6) and by the FDA (7).
    [Show full text]
  • "Macrolides"? Classify Each Drug in This Chapter As a Macrolide Or Azalide, and As an Antibiotic Or Semi-Synthetic Derivative
    STUDY GUIDE THE MACROLIDE/AZALIDE ANTIMICROBIAL AGENTS 1. Why are these antibiotics derivatives called "macrolides"? Classify each drug in this chapter as a macrolide or azalide, and as an antibiotic or semi-synthetic derivative. 2. What are the key structural differences between erythromycin, clarithromycin, azithromycin and dirithromycin? 3. Generally how does spiramycin and josamycin differ in structure from the commercial macrolides/azalides (2 reasons)? 4. What are the “ketolides and how do they differ in structure from the commercial macrolides? 5. What is the biosynthetic source of erythromycin? What is the lactone moiety of erythromycin called? What sugar moieties are present and what are their properties? 6. What hydrolysis product forms from erythromycin in aqueous acid or base? What is the significance of this reaction? Can it occur with other macrolides? 7. When does the “intramolecular cyclization” reaction occur with erythromycin? What is it's significance (two reasons) and how does it occur? Which functional groups are important for this reaction? 8. What salt forms of erythromycin are available? Which are water soluble? Which are water-insoluble? How is each salt form formulated and used (oral or parenteral)? 9. What ester and ester salt derivatives of erythromycin are available? What is the estolate? How is each salt form formulated and used (oral or parenteral)? What are the advantages of these esters dosage forms? 10. How does clarithromycin differ in structure from erythromycin? Why was this macrolide developed (the role of the 6-methoxy)? 11. How does azithromycin differ in structure from erythromycin? Why was this macrolide developed? 12. How does dirithromycin differ in structure from erythromycin? Why was this macrolide developed? What is the active form of this prodrug? 13.
    [Show full text]
  • Conference on Predicting Cell Metabolism and Phenotypes
    Conference on Predicting Cell Metabolism and Phenotypes Barry Bochner, Biolog, Inc., [email protected] Brief History of Metabolic Phenotypic Analysis In the beginning … The cell was a black box Early Beginnings of Metabolic Description of Cells Bergey’s Manual 1st Edition, 1923 L. E. den Dooren de Jong Survey of C-Source and N-Source Utilization, 1926 B. coli M. phlei Analogy #1 Metabolic Circuitry Resembles Electronic Circuits View of Cells circa 1960 Regulatory Complexity Added to Circuitry, circa 1970 feedback inhibition, synthetic pathways A B C D E F G feedforward activation, catabolic pathways Feedback and feedforward open up the possibility of oscillations Metabolic Oscillations Metabolic Oscillations A single gene mutation causes cell growth to oscillate ! Histidine secretion Histidine limitation Metabolism Resembles Electronic Circuit Diagrams Electrical Components Biological Components Dehydrogenases Polymerases Isomerases Kinases Glycosidases Hydrolases Phosphatases Epimerases Phosphorylases Transferases Peptidases Proteases Oxidoreductases Lyases Aldolases Ligases Hydroxylases Cyclases Higher Order Understanding of Electronic Circuits Amplifier Receiver Rectifier Oscillator Integrator Comparator Counter Filter Higher Order Understanding of Cells: Physiology • Growth is a property common to all cells • Cell growth is primarily polymer synthesis: DNA, RNA, protein, membranes, wall, storage polymers • The polymers are made by assembling subunits: deoxynucleotides, ribonucleotides, amino acids, etc. • The subunits are made from
    [Show full text]
  • Antiseptics and Disinfectants for the Treatment Of
    Verstraelen et al. BMC Infectious Diseases 2012, 12:148 http://www.biomedcentral.com/1471-2334/12/148 RESEARCH ARTICLE Open Access Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review Hans Verstraelen1*, Rita Verhelst2, Kristien Roelens1 and Marleen Temmerman1,2 Abstract Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and disinfectants in treating bacterial vaginosis (BV). Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (1970- 2010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A. Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria. Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide was slightly, though significantly less effective than a single oral dose of metronidazole.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith Et Al
    USOO9662400B2 (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith et al. (45) Date of Patent: *May 30, 2017 (54) METHODS FOR PRODUCING A (2013.01); C08B 37/003 (2013.01); C08L 5/08 BODEGRADABLE CHITOSAN (2013.01); A6 IK 38/00 (2013.01); A61 L COMPOSITION AND USES THEREOF 2300/404 (2013.01) (58) Field of Classification Search (71) Applicant: University of Memphis Research CPC ...... A61K 47/36; A61K 31/00; A61K 9/7007; Foundation, Memphis, TN (US) A61K 9/0024; A61 L 15/28: A61L 27/20; A61L 27/58: A61L 31/042; C08B 37/003 (72) Inventors: James Keaton Smith, Memphis, TN USPC ................................ 514/23, 40, 777; 536/20 (US); Ashley C. Parker, Memphis, TN See application file for complete search history. (US); Jessica A. Jennings, Memphis, (56) References Cited TN (US); Benjamin T. Reves, Memphis, TN (US); Warren O. U.S. PATENT DOCUMENTS Haggard, Bartlett, TN (US) 4,895,724. A * 1/1990 Cardinal .............. A61K9/0024 424,278.1 (73) Assignee: The University of Memphis Research 5,541,233 A 7/1996 Roenigk Foundation, Memphis, TN (US) 5,958,443 A 9/1999 Viegas et al. 6,699,287 B2 3/2004 Son et al. (*) Notice: Subject to any disclaimer, the term of this 6,989,157 B2 1/2006 Gillis et al. patent is extended or adjusted under 35 7,371.403 B2 5/2008 McCarthy et al. 2003, OO15825 A1 1/2003 Sugie et al. U.S.C. 154(b) by 0 days. 2003/0206958 A1 11/2003 Cattaneo et al.
    [Show full text]
  • 35 Cyproterone Acetate and Ethinyl Estradiol Tablets 2 Mg/0
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrCYESTRA®-35 cyproterone acetate and ethinyl estradiol tablets 2 mg/0.035 mg THERAPEUTIC CLASSIFICATION Acne Therapy Paladin Labs Inc. Date of Preparation: 100 Alexis Nihon Blvd, Suite 600 January 17, 2019 St-Laurent, Quebec H4M 2P2 Version: 6.0 Control # 223341 _____________________________________________________________________________________________ CYESTRA-35 Product Monograph Page 1 of 48 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................................. 3 INDICATION AND CLINICAL USE ..................................................................................................... 3 CONTRAINDICATIONS ........................................................................................................................ 3 WARNINGS AND PRECAUTIONS ....................................................................................................... 4 ADVERSE REACTIONS ....................................................................................................................... 13 DRUG INTERACTIONS ....................................................................................................................... 16 DOSAGE AND ADMINISTRATION ................................................................................................ 20 OVERDOSAGE ....................................................................................................................................
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas Et Al
    US 20130253 056A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas et al. (43) Pub. Date: Sep. 26, 2013 (54) CONTINUOUS ADMINISTRATION OF (60) Provisional application No. 61/179,511, filed on May LEVODOPA AND/OR DOPA 19, 2009. DECARBOXYLASE INHIBITORS AND COMPOSITIONS FOR SAME Publication Classification (71) Applicant: NEURODERM, LTD., Ness-Ziona (IL) (51) Int. Cl. A63L/216 (2006.01) (72) Inventors: Mara Nemas, Gedera (IL); Oron (52) U.S. Cl. Yacoby-Zeevi, Moshav Bitsaron (IL) CPC .................................... A6 IK3I/216 (2013.01) USPC .......................................................... 514/538 (73) Assignee: Neuroderm, Ltd., Ness-Ziona (IL) (57) ABSTRACT (21) Appl. No.: 13/796,232 Disclosed herein are for example, liquid aqueous composi (22) Filed: Mar 12, 2013 tions that include for example an ester or salt of levodopa, or an ester or salt of carbidopa, and methods for treating neuro Related U.S. Application Data logical or movement diseases or disorders such as restless leg (63) Continuation-in-part of application No. 12/961,534, syndrome, Parkinson's disease, secondary parkinsonism, filed on Dec. 7, 2010, which is a continuation of appli Huntington's disease, Parkinson's like syndrome, PSP. MSA, cation No. 12/836,130, filed on Jul. 14, 2010, now Pat. ALS, Shy-Drager syndrome, dystonia, and conditions result No. 7,863.336, which is a continuation of application ing from brain injury including carbon monoxide or manga No. 12/781,357, filed on May 17, 2010, now Pat. No. nese intoxication, using Substantially continuous administra 8,193,243. tion of levodopa and/or carbidopa or ester and/or salt thereof.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Screening of a Composite Library of Clinically Used Drugs and Well
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Pharmacol Manuscript Author Res. Author Manuscript Author manuscript; available in PMC 2017 November 01. Published in final edited form as: Pharmacol Res. 2016 November ; 113(Pt A): 18–37. doi:10.1016/j.phrs.2016.08.016. Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine β-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer Nadiya Druzhynaa, Bartosz Szczesnya, Gabor Olaha, Katalin Módisa,b, Antonia Asimakopoulouc,d, Athanasia Pavlidoue, Petra Szoleczkya, Domokos Geröa, Kazunori Yanagia, Gabor Töröa, Isabel López-Garcíaa, Vassilios Myrianthopoulose, Emmanuel Mikrose, John R. Zatarainb, Celia Chaob, Andreas Papapetropoulosd,e, Mark R. Hellmichb,f, and Csaba Szaboa,f,* aDepartment of Anesthesiology, The University of Texas Medical Branch, Galveston, TX, USA bDepartment of Surgery, The University of Texas Medical Branch, Galveston, TX, USA cLaboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Greece dCenter of Clinical, Experimental Surgery & Translational Research, Biomedical Research Foundation of the Academy of Athens, Greece eNational and Kapodistrian University of Athens, School of Pharmacy, Athens, Greece fCBS Therapeutics Inc., Galveston, TX, USA Abstract Cystathionine-β-synthase (CBS) has been recently identified as a drug target for several forms of cancer. Currently no
    [Show full text]
  • Gait Analysis in Advanced Parkinson's Disease – Effect of Levodopa And
    ORIGINAL ARTICLE Gait Analysis in Advanced Parkinson’s Disease – Effect of Levodopa and Tolcapone Din-E Shan, Shwn-Jen Lee, Ling-Yi Chao, and Shyh-Ing Yeh ABSTRACT: Objective: To determine the therapeutic effect of levodopa/benserazide and tolcapone on gait in patients with advanced Parkinson’s disease. Methods: Instrumental gait analysis was performed in 38 out of 40 patients with wearing-off phenomenon during a randomized, double-blind, placebo- controlled trial of tolcapone. R e s u l t s : Gait analysis disclosed a significant improvement by levodopa/benserazide in walking speed, stride length and the range of motion of hip, knee and ankle joints. At the end of the study, both the UPDRS motor scores during off-period and the percentage of off time improved significantly using tolcapone. However, gait analysis could not confirm this improvement. With respect to levodopa/benserazide effect, the reduction in rigidity correlated with improved angular excursion of the ankle, whereas the decreased bradykinesia correlated with improved stride length and angular excursion of the hip and knee joints. Conclusion: The results of our gait analysis confirmed that in parkinsonian patients with fluctuating motor symptoms levodopa/benserazide, but not tolcapone, produced a substantial improvement. RÉSUMÉ: Analyse de la démarche chez les patients en phase avancée de la maladie de Parkinson – Effet de la lévodopa et du tolcapone. Objectif: Le but de cette étude était de déterminer l’effet thérapeutique de la lévodopa/bensérazide et du tolcapone sur la démarche, chez les patients en phase avancée de la maladie de Parkinson. Méthodes: Une analyse instrumentale de la démarche a été réalisée chez 38 de 40 patients ayant un phénomène de détérioration de fin de dose pendant un essai randomisé, en double insu, contrôlé par placebo, du tolcapone.
    [Show full text]
  • 1 Brief Report: the Virucidal Efficacy of Oral Rinse Components Against SARS-Cov-2 in Vitro Evelina Statkute1†, Anzelika Rubin
    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.13.381079; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Brief Report: The Virucidal Efficacy of Oral Rinse Components Against SARS-CoV-2 In Vitro Evelina Statkute1†, Anzelika Rubina1†, Valerie B O’Donnell1, David W. Thomas2† Richard J. Stanton1† 1Systems Immunity University Research Institute, Division of Infection & Immunity, School of Medicine, Heath Park, Cardiff, CF14 4XN 2Advanced Therapies Group, School of Dentistry, Cardiff University, Heath Park, Cardiff CF14 4XY, UK †These authors contributed equally * Correspondence: [email protected], [email protected] Running title: Virucidal Activity of Mouthwashes Keywords: SARS-CoV2, mouthwash, lipid, envelope Disclosure: Venture Life Group plc provided information on mouthwash formulations employed in the study, but had no role in funding, planning, execution, analysis or writing of this study. A separate study funded to Cardiff University by Venture Life Group is assessing in vivo efficacy of CPC in patients with COVID19. The investigators declare no direct conflicts exist. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.11.13.381079; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license.
    [Show full text]
  • Tonsillopharyngitis - Acute (1 of 10)
    Tonsillopharyngitis - Acute (1 of 10) 1 Patient presents w/ sore throat 2 EVALUATION Yes EXPERT Are there signs of REFERRAL complication? No 3 4 EVALUATION Is Group A Beta-hemolytic Yes DIAGNOSIS Streptococcus (GABHS) • Rapid antigen detection test infection suspected? (RADT) • roat culture No TREATMENT EVALUATION No A Supportive management Is GABHS confi rmed? B Pharmacological therapy (Non-GABHS) Yes 5 TREATMENT A EVALUATE RESPONSEMIMS Supportive management TO THERAPY C Pharmacological therapy • Antibiotics Poor/No Good D Surgery, if recurrent or complicated response response REASSESS PATIENT COMPLETE THERAPY & REVIEW THE DIAGNOSIS© Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B269 © MIMS Pediatrics 2020 Tonsillopharyngitis - Acute (2 of 10) 1 ACUTE TONSILLOPHARYNGITIS • Infl ammation of the tonsils & pharynx • Etiologies include bacterial (group A β-hemolytic streptococcus, Haemophilus infl uenzae, Fusobacterium sp, etc) & viral (infl uenza, adenovirus, coronavirus, rhinovirus, etc) pathogens • Sore throat is the most common presenting symptom in older children TONSILLOPHARYNGITIS 2 EVALUATION FOR COMPLICATIONS • Patients w/ sore throat may have deep neck infections including epiglottitis, peritonsillar or retropharyngeal abscess • Examine for signs of upper airway obstruction Signs & Symptoms of Sore roat w/ Complications • Trismus • Inability to swallow liquids • Increased salivation or drooling • Peritonsillar edema • Deviation of uvula
    [Show full text]